1037 / 1835
Combined modality therapy has been the standard of care
for most patients with localized diffuse large B-cell
lymphoma (DLBCL), particularly those with limited stage low
risk disease or bulky sites
|
|
1037 / 1835
Combined modality therapy has been the standard of care
for most patients with localized diffuse large B-cell
lymphoma (DLBCL), particularly those with limited stage low
risk disease or bulky sites